Market open

Glaukos/$GKOS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Ticker

$GKOS

Trading on

NYSE

Industry

Health Care Equipment & Supplies

Employees

995

Glaukos Metrics

BasicAdvanced
$5.3B
-
-$2.77
1.05
-
$5.3B
1.05
$163.71
$77.91
1.1M
5.987
5.054
13.482
13.805
-10.77%
-7.06%
-23.83%
13.003
6.96
12.2
-73.744
21.85%
-0.21%
9.26%
37.38%

What the Analysts think about Glaukos

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Glaukos stock.

Glaukos Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Glaukos Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GKOS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Glaukos stock?

Glaukos (GKOS) has a market cap of $5.3B as of April 16, 2025.

What is the P/E ratio for Glaukos stock?

The price to earnings (P/E) ratio for Glaukos (GKOS) stock is 0 as of April 16, 2025.

Does Glaukos stock pay dividends?

No, Glaukos (GKOS) stock does not pay dividends to its shareholders as of April 16, 2025.

When is the next Glaukos dividend payment date?

Glaukos (GKOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Glaukos?

Glaukos (GKOS) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.